Objective Dostarlimab, a humanized monoclonal PD-1 blocking antibody, is being tested as
a cancer therapy in this review. Specifically, it addresses mismatch repair failure in …

Abstract Type IIA topoisomerase (TOP2A) is significantly associated with malignant tumor
development, invasion, treatment and its prognosis, and has been shown to be a therapeutic …

Highlights•A systematic review on cross-talk of dostarlimab with adaptive immunity and its
clinical trials, which are now being proven as breakthrough.•Recent developments in …

The two major challenges in cancer treatment are reducing the side effects and minimizing
the cost of cancer treatment. A better therapy to treat cancer remains to be developed …

Background Edible and medicinal herbs 1 (EMHs) refer to a class of substances with dual
attribution of food and medicine. These substances are traditionally used as food and also …

Predictive biomarkers for immune checkpoint inhibitors (ICIs) in solid tumors such as
melanoma, hepatocellular carcinoma (HCC), colorectal cancer (CRC), non-small cell lung …

Hypoxia in solid tumors heightens their invasiveness and resistance to therapy, presenting a
formidable obstacle in tumor therapy. The hypoxia prodrug Banoxantrone (AQ4N) …

Recent advancements in oncology have led to the development of histology-agnostic
therapies, which target genetic alterations irrespective of the tumor's tissue of origin. This …

Simple Summary This manuscript discusses the ongoing challenge of cancer as a leading
global cause of death despite advancements in therapies. It highlights the role of …

The inhibition of the TIGIT/PVR interaction demonstrates considerable anticancer properties
by enhancing the cytotoxic activity of natural killer (NK) and CD8+ T cells. However, the …